null

null

null

null

null

null

null

null

null

null

null

null

null

null

-3.24x Total Debt / Equity (Negative equity)

20bps rate rise adds ~$30M annual interest expense on ~$7B long-term debt; investment-grade BBB rating limits refinancing risk but thin 1.5% net margins amplify sensitivity

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Wuhan/China generic API manufacturing and Indian pharmaceutical export controls represent top two chokepoints for McKesson's drug distribution supply chain

Canada (CAD) and Europe (GBP/EUR) are top international markets; CAD/USD and GBP/USD volatility creates ~$200-400M revenue translation risk; hedging posture is limited

~85% US revenue; Canada (~10%) exposed to CAD devaluation; European operations (~5%) exposed to GBP/EUR; sovereign devaluation risk is moderate but manageable given USD dominance

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

AmerisourceBergen and Cardinal Health are peers not suppliers; McKesson depends on top 10 pharma manufacturers (Pfizer, AbbVie, etc.) representing ~60% of drug volume with limited substitutability

Pharmaceutical distribution is primarily on-premise and EDI-based; cloud disruption risk is low-to-moderate; 30-day cloud termination would disrupt analytics/ERP but not core distribution ops

Secondary technology/services segment (ClarusONE, RxTS) has higher cloud dependency; disruption would impair pharmacy technology services but represents <10% of total revenue

API coupling risk is low for core distribution; pharmacy technology clients face moderate switching costs via proprietary dispensing and workflow integrations (RelayHealth, CoverMyMeds)

Fails Howey Test; McKesson's revenue model is pharmaceutical distribution and services — no investment contract, profits not derived from third-party efforts; securities risk is negligible

Very High

Handles protected health information under HIPAA; GDPR exposure via Canadian/European ops is moderate; CCPA applies to California patient/customer data; compliance infrastructure is established

High exposure; McKesson holds ~33% US drug distribution market share alongside two rivals (oligopoly); DOJ/FTC scrutiny ongoing; opioid settlement liability already exceeded $7.9B

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~90% transactional (drug distribution volume-based); ~10% recurring via technology/services contracts; revenue is highly volume-dependent and not subscription-driven

Primary monetization via distribution margin (buy-sell spread) on pharmaceutical products; secondary via service fees in pharmacy technology and oncology management platforms

Spread-based pricing highly compressed (<1% gross margin on distribution); stress scenario of 10% generic price deflation could reduce gross profit by ~$500M; limited pricing power buffer

2/5; McKesson is a price-taker in generic distribution; branded drug pricing provides modest fee leverage but regulatory and PBM pressure caps upside; pricing power is structurally weak

3.6% Gross Margin (Thin (<20%))

No free-rider problem; distribution relationships are contractual with health systems, pharmacy chains, and independents; churn risk is moderate as Walgreens (major client) has partial self-distribution capability

Revenue growth is sublinear to headcount; distribution is capital and logistics-intensive; doubling revenue requires ~20-30% headcount increase due to warehouse automation and technology leverage

Marginal cost of incremental distribution volume is low (~0.1-0.2% of revenue); technology segment has near-zero marginal cost for software; overall model is moderately scalable

Not a franchise model; independent pharmacy network (Health Mart, ~4,800 stores) creates compliance drift risk around reimbursement, dispensing accuracy, and DEA controlled substance protocols

At 10x scale, unit economics deteriorate due to antitrust limits and market saturation (~33% share already); CAC for health system accounts is high; GPO dependency increases pricing pressure

Weak network effects; scale provides procurement leverage with manufacturers but not true demand-side network effects; CoverMyMeds has moderate two-sided network effect (providers/payers)

7.5% Return on Assets (Excellent)

Tier 1 recession-resistant; pharmaceutical demand is largely inelastic; 2008-2009 revenue grew ~5%; essential healthcare distribution insulates McKesson from cyclical downturns

Retail pharmacy chains (Walmart, Rite Aid, Health Mart independents) represent largest customer segment; Rite Aid bankruptcy (~5% revenue exposure) illustrates concentration risk

Health systems and hospital networks (IDNs) represent secondary segment; top 10 health system customers likely represent 15-20% of segment revenue with multi-year GPO-linked contracts

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.1% CapEx / Revenue (Low-CapEx Asset-Light)

0000927653

MCK